Anti-EGFR therapy including cetuximab and panitumumab significantly improves the survival of KRAS wild-type MSKCC, but not of those with KRAS-mutant cancer [25], suggesting that the single-drug therapy of cetuximab is insufficient to achieve a therapeutic effect. The gene discussed is EGFR; the disease is cancer.